ZBHZimmer Biomet

$89.12-10% 1Y

$89.12

$79.5852 weeks$103.42

ZBH in its own filings

Nothing in ZBH's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

506

Events found in the filings · across 2,644 filings · the record starts in 2001

Hard flags: none
Hard flags
Most recent filing: Sep 8, 2026
Most recent filing · Form 8-K
Record starts: Jul 16, 2001
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 4, 2026
Change in certifying accountant2 occurrences: 2005-05-20
Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares: 2022-12-13
SEC comment-letter activity34 occurrences: 2018-09-05

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 8, 2026On September 8, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured.Director or officer change · Form 8-K
Aug 5, 2026In the quarter ended March 31, 2026, the responsibilities of certain senior leaders who report to our chief operating decision maker (“CODM”) and the related operating profit information that these leaders present to the CODM changed.Other event · Form 8-K
Aug 5, 2026Second Quarter 2026 Financial Results.Earnings release · press release
Jun 29, 2026On June 26, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below.Material agreement entered · Form 8-K
May 12, 2026Zimmer Biomet Increases Share Repurchase Expectations.Regulation FD disclosure · press release
Apr 28, 2026On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity.Director or officer change · Form 8-K
Apr 28, 2026First Quarter 2026 Financial Results.Earnings release · press release
Feb 10, 2026Fourth Quarter and Full-Year 2025 Financial Results.Earnings release · press release
Jan 12, 2026On January 8, 2026, Mark Bezjak, a named executive officer in the 2025 proxy statement of Zimmer Biomet Holdings, Inc. (the “Company”), informed the Company that he will resign his employment, including all officer positions with the Company and its affiliates, effective as of January 16, 2026, to pursue another …Director or officer change · Form 8-K
Nov 5, 2025Third Quarter 2025 Financial Results.Earnings release · press release
Oct 7, 2025As previously disclosed in the Current Report on Form 8-K filed by Zimmer Biomet Holdings, Inc. (the “Company”) on July 14, 2025 with the Securities and Exchange Commission, on July 11, 2025, the Company, entered into an Agreement and Plan of Merger with Monogram Technologies Inc., a Delaware corporation (“Monogram”) …Other event · Form 8-K